Prostate cancer diagnosis and staging errors
- 作者: Al-Shukri S.1, Borovets S.1, Rybalov M.1
-
隶属关系:
- St.-Petersburg State I. P. Pavlov Medical University
- 期: 卷 3, 编号 1 (2013)
- 页面: 23-27
- 栏目: Articles
- URL: https://journals.rcsi.science/uroved/article/view/2504
- DOI: https://doi.org/10.17816/uroved3123-27
- ID: 2504
如何引用文章
详细
This review is analyzing advantages and disadvantages of basic methods for prostate cancer diagnostics and staging. Latest high-tech staging methods and nomograms are demonstrated. Causes of the errors occurring during prostate cancer diagnosing and staging are examined.
作者简介
Salman Al-Shukri
St.-Petersburg State I. P. Pavlov Medical University
Email: al-shukri@mail.ru
doctor of medical science, professor, head of the department. Department of Urology
Sergey Borovets
St.-Petersburg State I. P. Pavlov Medical Universitydoctor of medical science, senior researcher. Department of Urology
Maksim Rybalov
St.-Petersburg State I. P. Pavlov Medical Universitypostgraduate. Department of Urology
参考
- Чиссов В. И., Русаков И. Г. Заболеваемость раком предстательной железы в Российской Федерации // Экспериментальная и клиническая урология. — 2011. — № 2–3. — С. 6–7.
- Quinn M., Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons // B. J. U. Int. — 2002. — Vol. 90, N 2. — P. 162–173.
- Ilic D., O’Connor D., Green S., Wilt T. J. Screening for prostate cancer: a Cochrane systematic review // Cancer Causes Control. — 2007. — Vol. 18, N 3. — P. 279–285.
- Andriole G. L., Crawford E. D., Grubb R. L. 3rd. et al. Mortality results from a randomized prostate-cancer screening trial // N. Engl. J. Med. — 2009. — Vol. 360, N 13. — P. 1310–1319.
- Schröder F. H., Hugosson J., Roobol M. J. et al. Screening and prostate-cancer mortality in a randomized European study // N. Engl. J. Med. — 2009. — Vol. 360, N 13. — P. 1320–1328.
- Schröder F. H., van der Maas P., Beemsterboer P. et al. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer // J. Natl. Cancer Inst. — 1998. — Vol. 90, N 23. — P. 1817–1823.
- Semjonow A., Brandt B., Oberpenning F. et al. Discordance of assay methods creates pitfalls for the interpretation of prostate-specific antigen values // Prostate. — 1996. — Suppl. 7. — P. 3–16.
- Thompson I. M., Pauler D. K., Goodman P. J. et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter // N. Engl. J. Med. — 2004. — Vol. 350, N 22. — P. 2239–2246.
- Heidenreich A., Bellmunt J., Bolla M. et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease // Eur. Urol. — 2011. — Vol. 59, N 1. — P. 61–71.
- Carter H. B., Pearson J. D., Metter E. J. et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease // JAMA. — 1992. — Vol. 267, N 16. — P. 2215–2220.
- Schmid H.-P., McNeal J. E., Stamey T. A. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume // Cancer. — 1993. — Vol. 71, N 6. — P. 2031–2040.
- Catalona W. J., Partin A. W., Slawin K. M. et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicentre clinical trial // JAMA. — 1998. — Vol. 279, N 19. — P. 1542–1547.
- Deras I. L., Aubin S. M., Blase A. et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome // J. Urol. — 2008. — Vol. 179, N 4. — P. 1587–1592.
- Eichler K., Hempel S., Wilby J. et al. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review // J. Urol. — 2006. — Vol. 175, N 5. — P. 1605–1612.
- Donovan J., Hamdy F., Neal D. et al. Prostate Testing for Cancer and Treatment (ProtecT) feasibility study // Health Technol. Assess. — 2003. — Vol. 7, N 14. — P. 1–32.
- Матвеев Б. П. Клиническая онкоурология. — М.: Вердана, 2003. — 717 с.
- Spigelman S. S., McNeal J. E., Freiha F. S., Stamey T. A. Rectal examination in volume determination of carcinoma of the prostate: clinical and anatomical correlations // J. Urol. — 1986. — Vol. 136, N 6. — P. 1228–1230.
- Partin A. W., Carter H. B., Chan D. W. et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumour differentiation, tumour volume and benign hyperplasia // J. Urol. — 1990. — Vol. 143, N 4. — P. 747–752.
- Hudson M. A., Bahnson R. R., Catalona W. J. Clinical use of prostate specific antigen in patients with prostate cancer // J. Urol. — 1989. — Vol. 142, N 4. — P. 1011–1017.
- Enlund A., Pedersen K., Boeryd B., Varenhorst E. Transrectal ultrasonography compared to histopathological assessment for local staging of prostatic carcinoma // Acta Radiol. — 1990. — Vol. 31, N 6. — P. 597–600.
- Sauvain J. L., Palascak P., Bourscheid D. et al. Value of power and 3D vascular sonography as a method for diagnosis and staging of prostate cancer // Eur. Urol. — 2003. — Vol. 44, N 1. — P. 21–30; discussion 30–31.
- Zalesky M., Urban M., Smerhovský Z. et al. Value of power Doppler sonography with 3D reconstruction in preoperative diagnostics of extraprostatic tumor extension in clinically localized prostate cancer // Int. J. Urol. — 2008. — Vol. 15, N 1. — P. 68–75; discussion 75.
- Fuchsjager M., Shukla-Dave A., Akin O. et al. Prostate cancer imaging // Acta Radiol. — 2008. — Vol. 49, N 1. — P. 107–120.
- Simmons L. A., Autier P., Zát'ura F. et al. Detection, localisation and characterisation of prostate cancer by prostate HistoScanning (™) // B. J. U. Int. — 2012. — Vol. 110, N 1. — P. 28–35.
- Cooperberg M. R., Freedland S. J., Pasta D. J. et al. Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy // Cancer. — 2006. — Vol. 107, N 10. — P. 2384–2391.
- Partin A. W., Mangold L. A., Lamm D. M. et al. Contemporary update of the prostate cancer staging nomograms (Partin Tables) for the new millennium // Urology. — 2001. — Vol. 58, N 6. — P. 843–848.
- Whitmore W. F. Jr. Natural history and staging of prostate cancer // Urol. Clin. North Am. — 1984. — Vol. 11, N 2. — P. 205–220.
- Wolff J. M., Ittel T. H., Borchers H. et al. Metastatic workup of patients with prostate cancer employing alkaline phosphatase and skeletal alkaline phosphatase // Anticancer Res. — 1999. — Vol. 19, N 4A. — P. 2653–2655.
- Rana A., Karamanis K., Lucas M. G., Chisholm G. D. Identification of metastatic disease by T category, Gleason score and serum PSA level in patients with carcinoma of the prostate // Br. J. Urol. — 1992. — Vol. 69, N 3. — P. 277–281.